FDA
-
-
-
-
-
-
-
Annovis partners with NeuroRPM for AI biomarker platform in PD study
-
-
-
-
-
-
-
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
-
-
-
-
-
-
-
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
-
-
-
-
-
-
-
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
-
-
-
-
-
-
-
Annovis to Host Year-End Investor Webcast on December 11, 2024
-
-
-
-
-
-
-
Annovis Bio Inc. (ANVS) Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
-
-
-
-
-
-
-
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

